☎ (888) 264-7050
← Back to Blog Safety

What OSHA's New Naloxone Guidance Asks of Your Workplace First Aid Program

OSHA Fact Sheet 4519 recommends stocking opioid overdose reversal medications. No OSHA standard requires naloxone. Here is what your first aid program owes.

by iSi Environmental

On September 24, 2026, OSHA published Fact Sheet DSG FS-4519, “Opioid Overdose Rescue with Reversal Medications”. It tells employers to keep FDA-approved reversal medications on hand, treat the overdose kit like first aid supplies in plain view, train workers to spot the symptoms, and call 911 every time. It names naloxone and nalmefene, the two the FDA has approved.

The same document carries OSHA’s standard publication disclaimer: “It does not impose any new compliance requirements.”

Both are true at once, and the second is what your general counsel will ask about. No OSHA standard makes workplace naloxone mandatory, and 4519 came through no rulemaking.

The reason to keep reading is the comparison OSHA chose. The fact sheet says to keep naloxone in visible, easy to reach locations such as with automated external defibrillators, and no federal OSHA standard requires an AED either. They are in airport concourses and plant break rooms anyway, because employers ran the response-time arithmetic instead. Opioid overdose sits in the same space: respiratory arrest, minutes to hypoxic brain injury, and a trained bystander in between.

Four answers to one question, and only one of them is a requirement

These rows carry different force.

SourceWhat it says about naloxone at workForce
OSHA Fact Sheet 4519 (Sept. 24, 2026)Keep reversal medications on hand; treat the kit like first aidRecommendation, imposes no compliance requirement
ANSI/ISEA Z308.1-2026 (Sept. 17, 2026)Naloxone added to the workplace first aid kit standardRecommended item in a voluntary consensus standard
29 CFR 1910.151 and 1926.50Trained first aid responders and adequate supplies where definitive care is not closeRequirement, and it names no medication at all
N.Y. Labor Law section 27-f (approx. Dec. 12, 2026)Covered employers must have an opioid antagonist availableRequirement, New York only
OSHA enforcement historyNothingNo citation, settlement or Review Commission decision located

What does OSHA’s new naloxone fact sheet actually say?

Fact Sheet DSG FS-4519, dated 9/2026 and released September 24, 2026 under news release 26-1550-NAT, runs five sections: how reversal medications work, six acquisition routes, storage and supply management, key training topics, and federal resource links. It names naloxone and nalmefene as the FDA-approved options.

OSHA issued it under the Great American Recovery Initiative, framed by Acting Secretary of Labor Keith Sonderling as workforce policy rather than enforcement. The limit OSHA puts on it is explicit: the medications do not replace emergency services, their effects are temporary, and the first training topic listed is calling 911 even if the person wakes up.

Does OSHA require employers to stock naloxone?

No. Fact Sheet 4519 states in its own text: “It does not impose any new compliance requirements.” No OSHA standard mandates workplace naloxone or nalmefene. OSHA recommends keeping reversal medications on hand and treating the kits like AEDs. The enforceable first aid duties sit at 29 CFR 1910.151 and 29 CFR 1926.50, and neither one names any medication.

A fact sheet cannot be cited. Any vendor telling your leadership that OSHA now requires naloxone in the kit is describing a rule that does not exist, and your program loses credibility the first time someone checks the CFR.

Does the new ANSI/ISEA first aid kit standard require naloxone in our kits?

No. ANSI/ISEA Z308.1-2026, released September 17, 2026 as the standard’s sixth revision, adds naloxone as a recommended item, suggesting at least two nasal sprays in clearly labeled kits stored in plain view. It is a voluntary consensus standard, and OSHA cites only earlier editions of it, as examples, in the non-mandatory appendices to 1910.151 and 1926.50, which puts it three steps from a mandate.

Trade coverage has read as though workplace first aid kits must now contain naloxone. They do not. ISEA’s own announcement calls it recommended, and ISEA framed the decision as a hazard assessment: “First aid supplies should be ready for the emergencies most likely to happen in your workplace… For millions of American workers, that now includes an opioid overdose.”

The standards that actually bind you

Two first aid standards and one statutory clause carry the real obligations, and none mentions a drug.

What does 29 CFR 1910.151 actually require?

Three things. Ready availability of medical personnel for advice and consultation on plant health matters. Adequately trained first aid responders plus readily available supplies where no infirmary, clinic or hospital is in near proximity. Quick drench facilities where corrosives are present. Appendix A on kit contents is expressly non-mandatory, and nothing in the standard specifies a medication.

“Near proximity” is where the analysis lives. OSHA’s long-standing position is that emergency care must be available within no more than three to four minutes where serious injuries such as falls or electrocution are possible, and that “a somewhat longer response time of up to 15 minutes may be reasonable in workplaces, such as offices, where the possibility of such serious work-related injuries is more remote” (January 16, 2007 interpretation). The trigger is distance from definitive care, not any particular hazard.

Two clauses get overlooked. 1926.50(d)(2) requires construction first aid kits to be checked before each job and at least weekly on the job so expended items are replaced, so a reversal medication in a construction kit lands on a weekly kit check by operation of the standard, a natural point to confirm expiration dates. And 1910.151(a) already requires medical personnel to be readily available for advice and consultation, which makes that provider the natural person to consult before you add any medication.

Can OSHA cite us for not having naloxone on site?

No citation, news release or Occupational Safety and Health Review Commission decision involving workplace naloxone or overdose response failure was located. Any theory runs through the General Duty Clause, 29 USC 654(a)(1), where OSHA must prove four elements including a recognized hazard and a feasible method of correction. The 2026 maximums stand at $16,550 per serious and $165,514 per willful or repeated violation, frozen at 2025 levels after OMB cancelled the inflation adjustment.

The empty enforcement record is the most useful fact here. Searches of OSHA news releases, the interpretation index and published OSHRC decisions turned up nothing.

Element one explains why. It asks whether a worker experiencing an opioid overdose on your premises is a hazard of the employment, or a medical emergency that happens to occur at work. For most employers it is the second. The analysis shifts where workers handle opioids occupationally or respond to overdoses as part of the job, in healthcare, corrections and law enforcement. There, hazard recognition is satisfiable, and 4519 is public evidence that a feasible abatement method exists. Plaintiffs’ counsel gets there before OSHA does, because negligence runs on foreseeability.

Your exposure today is the first aid standard itself. A facility that fails the near proximity test with no trained responders is citable right now under 1910.151(b). The same hole shows up in post-impact response, which is why OSHA’s silence on head injury protocols leaves so many written programs short.

Whether your site needs it is a response-time question

Does my workplace actually need naloxone?

BLS recorded 410 fatal work injuries from drug or alcohol overdose in 2024, 8.1% of all 5,070 workplace deaths that year. NIOSH found elevated rates in construction and extraction, transportation, mining and healthcare, with construction and extraction workers in Massachusetts data at 151 opioid-related deaths per 100,000, six times the all-worker rate. Response time, public access and EMS distance drive the decision more than industry code does.

The trend runs opposite to the marketing. Workplace overdose deaths fell 19.9% between 2023 and 2024, from 512 to 410. Nationally, CDC and NCHS estimated 69,973 drug overdose deaths in 2025 against 81,313 in 2024, down almost 14% and the third consecutive annual decline, with opioid-involved deaths falling from 55,296 to 44,564. Anyone selling naloxone on a worsening-crisis story is working from 2023 data.

Stocking it was never a trend case. It is a per-event survivability case, and that arithmetic does not care that the event is rarer this year. A grain facility, well site or quarry 20 minutes from the nearest emergency department already failed the near proximity test on its other hazards and already keeps trained responders, which makes a reversal medication a marginal addition. A low-hazard office minutes from a hospital, with no public access, has no compliance driver here at all.

New York took the federal standard that requires nothing and made it a switch

Multi-state programs should read this twice. New York Labor Law section 27-f, enacted as Chapter 621 of 2025 (A2725-A) and amended by Chapter 17 of 2026 (A9453), requires covered employers to have an opioid antagonist available for first aid or emergency treatment at the workplace, effective roughly December 12, 2026.

Look at how the statute defines a covered employer: those “federally mandated to have first aid supplies readily available.” New York bolted its requirement onto the 1910.151(b) trigger. The federal standard that does not require naloxone is the mechanism a state used to require it.

The move is available to any legislature and cheap to copy, because it borrows an existing federal test. It also means an employer whose 1910.151 posture is undocumented cannot tell whether it is covered.

Do Kansas, Oklahoma, Texas, Missouri, Nebraska or Colorado require workplace naloxone?

We found no workplace naloxone mandate in any of the six. All six are federal OSHA jurisdictions with no approved State Plan covering private-sector workers, so 1910.151, 1926.50 and Part 1904 apply exactly as written, and no state program can layer a naloxone requirement on top. Naloxone nasal spray has been sold over the counter nationwide since 2023, so layperson possession is not the barrier in any of them. New York remains the only genuine employer mandate relevant to a national program. State and local government workers in those six states fall outside federal OSHA coverage entirely, which changes the analysis for a municipal client.

Am I protected if I give naloxone to a coworker and something goes wrong?

Protection is a state-law question and it is not uniform. Kansas immunity reaches “any patient, bystander, school nurse, or a first responder” acting in good faith and with reasonable care, excepting gross negligence (2025 Session Laws Ch. 73). Texas protects “a person who, acting in good faith and with reasonable care” administers or declines to administer (section 483.106). Oklahoma’s immunity names first responders and family members, with no express protection for an ordinary coworker.

StateWho is protected when administeringWorkplace mandate
KansasPatients, bystanders, school nurses, first responders in good faith with reasonable careNone
MissouriGood-faith administration, with a statutory duty to contact emergency personnel immediately afterNone
TexasAny person acting in good faith and with reasonable care, including the decision not to administerNone
OklahomaDesignated first responders and family members onlyNone
NebraskaLaypersons “in a position to assist” and responders, with immunity running to individuals and responder organizations’ liability expressly preservedNone
ColoradoLaypersons in good faith, no training mandate, and the statute “shall not be interpreted to establish any duty or standard of care” (C.R.S. 18-1-712)None

Read the table as a program design document. Missouri’s immediate-notification duty belongs verbatim in a Missouri site’s procedure. Nebraska’s immunity runs to individuals, so the organization’s own exposure is worth naming before anyone signs off. Oklahoma is the real gap, so an Oklahoma employer should route its program through the 1910.151(a) medical consultation relationship and document training. Colorado’s standing-order route under C.R.S. 12-30-110 runs through state-defined eligible entities, so confirm eligibility before relying on it; over-the-counter purchase is the acquisition route that needs no eligibility determination.

Colorado’s no-duty clause also answers the legal-risk objection 33% of employers gave the National Safety Council. Legislatures granting immunity for administering naloxone have declined to create a duty to have it.

Buying the kit is the small part

How do we add naloxone to our first aid program without creating new liability?

Fact Sheet 4519 lists six acquisition routes: retail pharmacy, wholesale or bulk purchase, standing orders, group purchasing organizations, manufacturer programs, and public health partnerships. Pair acquisition with the 1910.151(a) medical consultation relationship, OSHA’s training topics, assigned expiration oversight, and integration into the emergency action plan.

Integration is where programs fail, and the work is procedural. Somebody owns the kit, and OSHA suggests a safety officer: expiration dates, placement after every layout change, a responder roster that still matches the shift schedule. If your plan already routes a medical emergency through a named responder and a 911 call, overdose response is an amendment to a document you have. Get the plan types straight first, since an emergency action plan and an emergency response plan carry different obligations and 1910.38 governs the evacuation side rather than the medical side.

Training should mirror what OSHA published: recognizing slow or stopped breathing, blue lips or skin, pinpoint pupils and unresponsiveness; calling 911 even if the person wakes up; positioning and supportive care; treating people with respect; and connecting someone who experiences an overdose to ongoing care. Those last two are OSHA’s own topics, and they separate a program workers will use from one they hesitate over.

How should naloxone be stored, and how often does it expire?

Fact Sheet 4519 directs employers to “follow the storage conditions specified in the product labeling and keep away from direct light and excessive heat. Do not freeze this medication,” and to track labeled expiration dates under a named owner. FDA announced in January 2024 that newly manufactured Narcan 4 mg nasal spray carries a four-year shelf life, up from three.

The extension covers only product manufactured after the announcement, so anything on your shelf keeps its printed date. It answers one of four objections employers gave the NSC in its January 2024 survey of 502 employers: shelf life at 28%, legal-risk uncertainty at 33%, purchase cost at 30%, leadership skepticism at 28%. Only 28% stocked naloxone at all work sites. Cost and skepticism deserve an argument rather than a dismissal.

On administration, OSHA says one thing and stops: “More than one dose may be needed. Follow the dosage and administration instructions in the product labeling.” Route every clinical specific to the FDA product labeling and to whoever provides your medical direction under 1910.151(a).

This post is regulatory guidance, not medical advice. Clinical decisions belong to the product labeling and to your own medical provider.

Is the responder at risk from fentanyl exposure when helping an overdose victim?

The joint position statement of the American College of Medical Toxicology and the American Academy of Clinical Toxicology concludes that “incidental dermal absorption is unlikely to cause opioid toxicity,” and that fentanyl patches covering both palms would take roughly 14 minutes to deliver 100 mcg. Nitrile gloves suffice for routine handling. Inhalation of suspended particles is the route of genuine concern, where a fitted N95 or P100 is reasonable. Wash incidental skin contact with copious water.

This counter-signal cuts toward preparedness. The belief that touching a person who is overdosing could be dangerous is widespread, wrong, and a reason workers freeze at the moment closing the distance matters. A program that buys the nasal spray and leaves that belief in place has bought equipment without capability. Correct it in training, with the toxicology citation.

Is administering naloxone at work an OSHA recordable event?

It depends on work-relatedness, not on the naloxone. Under 1904.5(b)(2)(i) a person present as a member of the general public is never recordable, which covers most retail and property management events outright. Exception (b)(2)(ii) excludes symptoms that surface at work but result solely from an exposure outside the work environment. If the case is work-related, 1904.7(b)(6) makes loss of consciousness recordable on its own, whatever medication was given.

Work it in that order and most cases resolve at step one. A customer overdose in your parking structure carries no 300 log consequence. An employee who used off site and became symptomatic after arriving fits exception (b)(2)(ii), though the fit weakens if the use occurred on your property. Exception (b)(2)(vi), self-medication for a non-work-related condition, exists in theory and OSHA reads it tightly: in a March 21, 2016 interpretation on a hand injury where post-accident testing showed alcohol intoxication, OSHA declined to apply it and held the injury recordable. Do not stretch that case past its facts.

The first aid question is where the guidance runs out, and anyone answering it confidently is guessing. 1904.7(b)(5)(ii) is a closed list, and OSHA says so: “this is a complete list of all treatments considered first aid for part 1904 purposes.” It includes using a non-prescription medication at nonprescription strength, and nothing resembling an opioid antagonist. OSHA has held that issuing prescription medication is medical treatment beyond first aid, including preventive use, in the EpiPen context. Naloxone nasal spray has been available without a prescription since March 29, 2023, which arguably puts over-the-counter naloxone inside that line. OSHA has published no interpretation on the point, so document your reasoning in the case file rather than assert an answer.

In practice the loss-of-consciousness trigger settles most work-related cases before that debate matters. Note 1904.39: a work-related fatality requires an 8-hour report and in-patient hospitalization a 24-hour report.

Where this leaves your program this week

Three questions, answerable from documents you either have or do not. How long does emergency care take to reach each site, and is that written down anywhere. Does your emergency action plan name a responder and a notification chain for a medical emergency, or only for evacuation. And in New York, which sites meet the section 27-f coverage test.

If the answer to the first runs past four minutes at any site, the naloxone decision is the smaller of your two findings. The near proximity and trained-responder requirement under 1910.151(b) is citable today and does not depend on a fact sheet published four days ago. Nobody has been cited over naloxone. Employers get cited over first aid adequacy regularly. Confirm which written plans you owe while you are in there, since most facilities owe more emergency plans than they have drafted.

iSi’s safety program development work starts with that response-time and written-program inventory, site by site, and produces the procedure instead of a recommendation to write one. If you want to know whether adding a reversal medication to your kits is a purchasing decision or the first visible symptom of a first aid program that was never finished, call (316) 264-7050 and we will walk your sites with you.

Sources

OSHA, the guidance itself

OSHA, regulatory text, letters of interpretation and directives

BLS, workplace fatality data

CDC, NCHS and NIOSH

FDA, approvals and labeling

State statutes and enacted legislation

Consensus standard, employer survey and medical toxicology

Tags: